MEDIA center
ELND005 Phase II Clinical Study Data in Alzheimer's Disease
ELND005 Mechanism of Action in Alzheimer's Disease
- Safety and Efficacy Results of a Phase 2 Randomized, Placebo-Controlled, Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to Moderate Alzheimer’s Disease
Stephen Salloway et al.
[Original ICAD poster] [Reformatted version] - Imaging & Cerebrospinal Fluid Biomarker Results of a Phase 2 Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild/Moderate AD
Dr. Anton Porsteinson, William B and Sheila Konar on behalf of ELND005-AD201 investigators
[ICAD presentation] - Population Pharmacokinetic Analysis of Plasma, Cerebrospinal Fluid, and Brain ELND005 in Patients with Mild to Moderate Alzheimer’s Disease
Earvin Liang et al.
[Original ICAD poster] [Reformatted version] - A Phase 2 randomized trial of ELND005, scyllo-inositol, in mild-moderate Alzheimer’s disease
Salloway et al., Neurology, September 27, 2011 issue
[Link to Neurology]
ELND005 Mechanism of Action in Alzheimer's Disease
© 2011 Transition Therapeutics Inc.